Immunosuppression status of liver transplant recipients with hepatitis C affects biopsy-proven acute rejection
Clinical and Molecular Hepatology
;
: 366-371, 2016.
Artigo
em Inglês
| WPRIM
| ID: wpr-188163
ABSTRACT
BACKGROUND/AIMS:
The relationship between patient survival and biopsy-proven acute rejection (BPAR) in liver transplant recipients with hepatitis C remains unclear. The aims of this study were to compare the characteristics of patients with and without BPAR and to identify risk factors for BPAR.METHODS:
We retrospectively reviewed the records of 169 HCV-RNA-positive patients who underwent LT at three centers.RESULTS:
BPAR occurred in 39 (23.1%) of the HCV-RNA-positive recipients after LT. The 1-, 3-, and 5-year survival rates were 92.1%, 90.3%, and 88.5%, respectively, in patients without BPAR, and 75.7%, 63.4%, and 58.9% in patients with BPAR (P<0.001). Multivariate analyses showed that BPAR was associated with the non-use of basiliximab and tacrolimus and the use of cyclosporin in LT recipients with HCV RNA-positive.CONCLUSION:
The results of the present study suggest that the immunosuppression status of HCV-RNA-positive LT recipients should be carefully determined in order to prevent BPAR and to improve patient survival.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Recidiva
/
Biópsia
/
Proteínas Recombinantes de Fusão
/
RNA Viral
/
Reação em Cadeia da Polimerase
/
Taxa de Sobrevida
/
Estudos Retrospectivos
/
Transplante de Fígado
/
Tacrolimo
/
Ciclosporina
Tipo de estudo:
Estudo observacional
/
Estudo prognóstico
/
Fatores de risco
Limite:
Humanos
Idioma:
Inglês
Revista:
Clinical and Molecular Hepatology
Ano de publicação:
2016
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS